On 27 MAY Urban Outfitters, Inc. (NASDAQ:URBN) and Terrain announced that its Board of Directors has authorized the repurchase of 10 million common shares under a share repurchase program. Pursuant to this program, the Company, at its discretion, may repurchase its common shares from time to time, subject to market conditions and at prevailing market prices. Urban Outfitters, Inc. (NASDAQ:URBN) net profit margin is 8.70% and weekly performance is 2.77%. On last trading day company shares ended up $34.19. Analysts mean target price for the company is $42.23. Urban Outfitters, Inc. (NASDAQ:URBN) distance from 50-day simple moving average (SMA50) is -3.88%.
On 3 JUNE BP plc (ADR) (NYSE:BP) said that BP plc (ADR) (NYSE:BP) had requested the U.S. Circuit Court of Appeal to halt payments while the company lulls over judgment about the basis on which businesses could prove themselves to be qualified for payments. BP plc (ADR) (NYSE:BP) shares advanced 0.74% in last trading session and ended the day on $50.44. BP Gross Margin is 12.90% and its return on assets is 3.30%. BP plc (ADR) (NYSE:BP) quarterly performance is 4.58%.
Barnes & Noble, Inc. (NYSE:BKS) said it will develop a tablet with Samsung Electronics Co Ltd as it tries to revive its money-losing Nook digital business. Barnes & Noble, Inc. (NYSE:BKS) shares moved up 3.54% in last trading session and was closed at $19.57, while trading in range of $19.30 – $19.68. Barnes & Noble, Inc. (NYSE:BKS) year to date (YTD) performance is 30.90%.
The Gap Inc. (NYSE:GPS) reported that May net sales increased 4 percent compared with last year. Net sales for the four-week period ended May 31, 2014 were $1.27 billion compared with net sales of $1.22 billion for the four-week period ended June 1, 2013. The Gap Inc. (NYSE:GPS) ended the last trading day at $41.19. Company weekly volatility is calculated as 1.64% and price to cash ratio as 11.82. The Gap Inc. (NYSE:GPS) showed a positive/negative weekly performance of 0.81%.
On 4 JUNE Bayer AG (ADR) (OTCMKTS: BAYRY) announced the initiation of a new study on its pulmonary hypertension (PH) drug, Adempas (riociguat). The company initiated a phase IIb RISE-IIP (Riociguat in Patients with Symptomatic Pulmonary HypErtension associated with Idiopathic Interstitial Pneumonias) study (n=120) on Adempas, which will be evaluating the efficacy and safety of the drug in patients suffering from symptomatic PH associated with idiopathic interstitial pneumonia (IIP). Bayer AG (ADR) (OTCMKTS: BAYRY) on last trading day company shares ended up $143.32.